Science & Enterprise subscription

Follow us on Twitter

  • New contributed post on Science and Enterprise: Making an Excellent First Impression in Business
    about 2 hours ago
  • A research team in Europe and Israel is devising a new process for faster bio-printing of human organs with three-d…
    about 19 hours ago
  • New post on Science and Enterprise: High-Speed 3-D Organ Printing in Development #Science #Business
    about 19 hours ago
  • Medical and robotics labs at two universities in Pittsburgh are developing a portable, autonomous trauma care devic…
    about 24 hours ago
  • New post on Science and Enterprise: A.I., Robotics Studied for Military Trauma System #Science #Business
    about 24 hours ago

Please share Science & Enterprise

Follow by Email
Visit Us

Biomarker Diagnostics Company Gains $40M in Venture Funding

Loose bills of multiple denominations (borman818)Astute Medical Inc. in San Diego, a developer of biomarker-based medical diagnostics, says it completed $40.4 million in series C venture financing, the third cycle of funding after initial start-up. The funding round was led by MPM Capital and included new investor Kaiser Permanente Ventures, as well as existing investors De Novo Ventures, Delphi Ventures, Domain Associates, and Johnson & Johnson Development Corporation.

Astute Medical identifies and validates protein biomarkers that can be used for diagnosing diseases, particularly with labratory (in vitro) tests. The company’s current interests include tests involving abdominal pains, acute coronary syndromes, cerebrovascular injury (e.g., stroke), kidney injury, and sepsis.

The company plans to use the proceeds from the round to begin commercializing its first product, as well as advance and expand its research, development, and validation of biomarker-based lab tests. Details about its first commercial product were not disclosed.

Astute Medical was founded in 2007 by former executives in the diagnostics company Biosite Inc.  The company completed its series A funding round in May 2008, with $6.2 million led by DeNovo Ventures. Its series B round, was divided into two segments: $26.5 million in May 2010, and $13 million in March 2011.

Read more:

Hat tip: Fortune/Term Sheet

Photo: borman818/Flickr

*     *     *

Please share Science & Enterprise ...

Comments are closed.